Asia Pacific Artificial Intelligence In Drug Discovery Market Size & Outlook
- Healthcare IT
- AI in Healthcare
- Artificial Intelligence in Drug Discovery Market Outlook
- AI in Healthcare
Global Market
Related Markets
Ask Prism AI about the artificial intelligence in drug discovery market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Asia Pacific artificial intelligence in drug discovery market highlights
- The Asia Pacific artificial intelligence in drug discovery market generated a revenue of USD 439.8 million in 2025.
- The market is expected to grow at a CAGR of 27.2% from 2026 to 2033.
- In terms of segment, neurodegenerative diseases was the largest revenue generating therapeutic space in 2025.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 439.8 million |
| Market revenue in 2033 | USD 3,008.7 million |
| Growth rate | 27.2% (CAGR from 2026 to 2033) |
| Largest segment | Neurodegenerative diseases |
| Fastest growing segment | Other |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease, Other |
| Key market players worldwide | International Business Machines Corp, Exscientia PLC ADR, Insilico Medicine, Aitia, Alphabet Inc Class A, Benevolent AI, BioSymetrics, Atomwise, Insitro, Recursion Pharmaceuticals Inc Class A |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 18.8% of the global artificial intelligence in drug discovery market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,008.7 million by 2033.
Increasing patient pool, growing acceptance of cloud computing, and rising number of government programs supporting AI are primary factors expected to drive the market. In addition, increasing number of biopharmaceutical firms are applying AI to modernize the drug discovery process and AI application is found in the field of diagnostics.
For instance, in 2017, China’s Tencent introduced an AI-driven diagnostic medical imaging facility, called AI Medical Innovation System (AIMIS). The technology exhibited 90% and 95% accuracy for initial diagnoses of esophageal & lung cancers, respectively.
In April 2020, Cyclica announced a multiyear & multiproject collaboration with the Genome Institute of Singapore (GIS). The collaboration aims to carry out research efforts extending from polypharmacology profiling to novel compound design for diverse drug discovery programs in oncology & related diseases.
No credit card required*
Publish Date: Apr 21, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Artificial Intelligence In Drug Discovery Market Scope
Artificial Intelligence In Drug Discovery Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| International Business Machines Corp | View profile | 282,200 | One New Orchard Road, Armonk, NY, United States, 10504 | www.ibm.com |
| Alphabet Inc Class A | View profile | 180,895 | 1600 Amphitheatre Parkway, Mountain View, CA, United States, 94043 | www.abc.xyz |
| Exscientia PLC ADR | View profile | 483 | Oxford Science Park, The Schrodinger Building, Oxford, United Kingdom, OX4 4GE | www.exscientia.ai |
| Insilico Medicine | View profile | 101-250 | Hong Kong, Hong Kong Island, Hong Kong, Asia | www.insilico.com |
| Aitia | View profile | 51-100 | Somerville, Massachusetts, United States, North America | www.aitiabio.com/ |
| Benevolent AI | View profile | 248 | 4-8 Maple Street, London, United Kingdom, W1T 5HD | www.benevolent.com |
| Recursion Pharmaceuticals Inc Class A | View profile | 500 | 41 S Rio Grande Street, Salt Lake City,, UT, United States, 84101 | www.recursion.com |
| BioSymetrics | View profile | 11-50 | New York, New York, United States, North America | www.biosymetrics.com |
| Atomwise | View profile | 51-100 | San Francisco, California, United States, North America | www.atomwise.com |
| Insitro | View profile | 101-250 | South San Francisco, California, United States, North America | www.insitro.com |
Asia Pacific Artificial Intelligence in Drug Discovery Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Artificial Intelligence in Drug Discovery Market Outlook will help companies and investors design strategic landscapes.
Neurodegenerative Diseases was the largest segment with a revenue share of 27.65% in 2025.
Horizon Databook has segmented the Asia Pacific artificial intelligence in drug discovery market based on oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases, infectious disease, other covering the revenue growth of each sub-segment from 2021 to 2033.
Increasing patient pool, growing acceptance of cloud computing, and rising number of government programs supporting AI are primary factors expected to drive the market. In addition, increasing number of biopharmaceutical firms are applying AI to modernize the drug discovery process and AI application is found in the field of diagnostics.
For instance, in 2017, China’s Tencent introduced an AI-driven diagnostic medical imaging facility, called AI Medical Innovation System (AIMIS). The technology exhibited 90% and 95% accuracy for initial diagnoses of esophageal & lung cancers, respectively.
In April 2020, Cyclica announced a multiyear & multiproject collaboration with the Genome Institute of Singapore (GIS). The collaboration aims to carry out research efforts extending from polypharmacology profiling to novel compound design for diverse drug discovery programs in oncology & related diseases.
- Asia Pacific Artificial Intelligence In Drug Discovery Market Therapeutic Space Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Neurodegenerative Diseases
- Cardiovascular Disease
- Metabolic Diseases
- Infectious Disease
- Other
- Asia Pacific Artificial Intelligence In Drug Discovery Market Application Outlook (Revenue, USD Million , 2021-2033)
- Drug optimisation and repurposing
- Preclinical testing
- Others
Reasons to subscribe to Artificial Intelligence in Drug Discovery Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Artificial Intelligence in Drug Discovery Market Outlook databook
- Our clientele includes a mix of Artificial Intelligence in Drug Discovery Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Artificial Intelligence in Drug Discovery Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Artificial Intelligence in Drug Discovery Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Artificial Intelligence In Drug Discovery Market, 2021-2033 (US$M)
Asia Pacific artificial intelligence in drug discovery market statistics, by therapeutic space, 2021-2033 (US$M)
